GCM
KRON

Gladius Capital Management’s Kronos Bio KRON Stock Holding History

Gladius Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,313
Closed -$32.9K – 407
2022
Q4 		$32.9K Buy
20,313
+11,531
+131% +$26.5K ﹤0.01% 290
2022
Q3 		$30K Buy
+8,782
New +$39.6K ﹤0.01% 306

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Gladius Capital Management's KRON Position: Q1 2023 in Review

Gladius Capital Management sold out of Kronos Bio (KRON) in Q1 2023, closing a stake of 20,313 shares — an estimated $32.9K sold.

Gladius Capital Management first reported a position in KRON in Q3 2022 and held it in 2 quarters. The position peaked at $32.9K in Q4 2022. 87 funds tracked by Wall St. Rank hold KRON as of Q1 2023.

  • Gladius Capital Management reported no remaining Kronos Bio position as of Q1 2023 after selling out during the quarter.
  • Gladius Capital Management sold 20,313 Kronos Bio shares in Q1 2023, an estimated $32.9K.
  • Gladius Capital Management first reported a position in Kronos Bio in Q3 2022 and held it in 2 quarters.
  • Gladius Capital Management's Kronos Bio position peaked at $32.9K in Q4 2022.
  • 87 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2023.

Based on Gladius Capital Management's 13F filing for Q1 2023, filed 9 May 2023.